Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.
Following a strategic adjustment to its share capital structure, China's leading online recruitment platform Kanzhun Limited sees sustained bullish sentiment from Wall Street, with a majority of analysts maintaining Buy ratings and forecasting significant upside.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Despite a bruising year, XRP's legal clarity, banking ambitions, and technical upgrades position it as a speculative recovery play for investors eyeing the next market cycle.
Soybean prices extended their decline on Friday, pressured by lackluster export sales data and a broader commodity sell-off. With key commitments lagging last year's pace, traders are now looking ahead to next week's crush data for signs of domestic demand strength.
A dramatic reversal in precious metals markets saw silver crash 35% and gold fall 12% in a single session, testing a long-held crypto theory about capital rotation as Bitcoin demonstrates relative stability.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
In a market fixated on tech giants, savvy investors are looking to regional financial institutions for sustainable growth. We analyze two banks with strong momentum and one where caution may be warranted, against a backdrop of shifting interest rates and economic uncertainty.
Peter McGuinness, the CEO who sought to reposition plant-based meat for mainstream consumers by moving beyond climate messaging, is departing Impossible Foods. His exit comes as the broader alternative protein sector faces significant sales declines and strategic recalibration.
DXC Technology met Q4 revenue targets with stable sales of $3.19B and an earnings surprise, but cautious guidance and stagnant organic growth highlight the challenges of its strategic transformation toward AI-native services.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Nasdaq Inc. reported stronger-than-expected fourth-quarter results, fueled by surging revenue from its technology solutions division and strategic AI initiatives, even as the company navigates a tighter margin environment.
ManpowerGroup surpassed revenue forecasts in Q4 2025, reporting a 7.1% year-over-year increase to $4.71 billion. However, earnings fell short of expectations, highlighting the ongoing pressure on profitability even as demand shows signs of firming.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
The banking sector has surged 12.5% in six months, outpacing the broader market. Yet, beneath the headline gains, selectivity is key. We analyze one bank with a unique value proposition poised for sustainable growth and flag two others where the risk-reward appears less compelling for investors.
